2,354 material Form 8-K filings that 2,004 companies we cover made with the SEC in November 2026, each read and summarized by AI: what happened, the key figures, whether it reads positive or negative for shareholders, and how big a deal it is (impact 1-5). 1,081 of them were written later, when past filings were added: a selection, not every 8-K of the month (see the note below).
Solidion Technology reported third-quarter 2026 results, with revenue of $41,638 compared with $9,350 a year earlier and net income of approximately $244,000 compared with a net loss of $4.1 million in the prior-year period. Cash and cash equivalents were $26.2 million at September 30, 2026, and total liabilities fell about 40% from year-end 2025, which the company says supports its capacity to pursue acquisitions.
Q3 2026 revenue was $41,638, up from $9,350 in Q3 2025; basic EPS was $0.02 versus a loss of $1.33 per share.
Net income was approximately $244,000 for the quarter, compared with a net loss of $4.1 million in the prior-year period.
Cash and cash equivalents were $26.2 million at September 30, 2026, down from $27.7 million at June 30, 2026.
On September 13, 2026, the Board authorized repurchases of up to $1.0 million of common stock.
Upland Software entered a Dividend Waiver Agreement with Ulysses Aggregator, LP, an affiliate of HGGC and holder of all 115,000 Series A Convertible Preferred shares, under which dividend accrual on the preferred stock is waived for an indefinite period effective October 1, 2026. The company expects the waiver to improve net income attributable to common stockholders and per-share results beginning in the fourth quarter of 2026, and the filing gives no dollar amount for the waived dividends.
Ulysses Aggregator, LP, an affiliate of HGGC, holds all 115,000 outstanding Series A Preferred shares.
Series A dividends accrue at 4.5% per year, paid in kind; waiver is effective October 1, 2026.
Waived dividends are permanently forgiven, even if the waiver is revoked by a majority of Series A holders on 30 days' notice.
Upland expects the full quarterly benefit beginning in the fourth quarter of 2026.
On November 5, 2026, Our Bond, Inc. and Ascent Partners Fund LLC amended their Securities Purchase Agreement dated November 3, 2026. The amendment modifies certain covenant restrictions on the company's subsequent equity sales. The 8-K does not state the specific changes or any dollar amounts, so the effect on shareholders is not quantified in the filing.
Amendment dated November 5, 2026, to the Securities Purchase Agreement dated November 3, 2026, with Ascent Partners Fund LLC
Modifies covenant restrictions on the company's subsequent equity sales
Amendment filed as Exhibit 10.1; the 8-K does not give specific terms or figures
LASE Corp. said its Board appointed Sanjay Adhav and Chief Financial Officer Timothy A. Peterman as directors, effective November 3, 2026, to fill two existing vacancies. The company announced the appointments in a press release dated November 9, 2026, and the filing discloses no related-party transactions or arrangements for either appointee.
Board appointed Sanjay Adhav and CFO Timothy A. Peterman as directors, effective November 3, 2026, filling two existing vacancies
Adhav has served as President of Quantum Technology, Inc. since 2013; Peterman was CEO of iMedia Brands, Inc. from 2019 to 2023
Press release announcing the appointments was issued November 9, 2026 (Exhibit 99.1)
TechPrecision and its subsidiaries Ranor and Stadco entered a $10.0 million credit agreement with Rosenthal & Rosenthal on November 3, 2026, and used the proceeds to repay the prior Beacon Bank & Trust loan agreement. The facility includes a revolving line of up to $5.0 million and two term loans, and it requires a minimum quarterly tangible net worth of $5.5 million. The company also said it may be unable to file its Form 10-Q for the period ended September 30, 2026 on time.
Facility includes a $5.0 million revolving line, a $1.5 million three-year term loan and a $3.5 million five-year term loan, secured by substantially all personal property and a first mortgage on Ranor's Westminster, Massachusetts facility
Prior Beacon Bank & Trust loan agreement was terminated and repaid in full on November 3, 2026; closing costs were approximately $0.6 million.
Company issued 25,000 shares of common stock to the broker that introduced the lender.
Management expects the financing to alleviate the substantial doubt about going concern; tangible net worth was $7.6 million as of June 30, 2026 against the $5.5 million covenant.
Reliance Global Group, Inc. (EZRA) closed its acquisition of the Oblivus GPU cloud computing platform on November 3, 2026, paying $3,000,000 in cash at closing from cash on hand, with up to $750,000 more in milestone payments that depend on future revenue. The company says Oblivus generated about $1.5 million in revenue for the twelve months ended September 2026, based on unaudited seller records, and that the deal marks its entry into the AI infrastructure market. Shareholders should note that the company has not yet filed the required acquired-business financial statements and pro forma information, and that its trading symbol is set to change to XGPU on November 10, 2026.
Closing payment of $3,000,000 in cash; up to two $375,000 milestone payments tied to average monthly cash revenue of $79,000 and $120,000
Oblivus reported about $1.5 million in revenue for the twelve months ended September 2026, per seller's unaudited records
Consulting agreement with founder Matthew Antoun: $250,000 in cash fees over 12 months, plus stock up to $600,000 subject to Board approval
Trading symbol expected to change from EZRA to XGPU on Nasdaq at the open on November 10, 2026
Mueller Water Products furnished an updated investor presentation dated November 11, 2026, which reports results for the fiscal year ended September 30, 2026. Net sales were $1,475.0 million, up from $1,429.7 million in FY2025, and net income rose to $221.9 million from $191.7 million. Shareholders get a fuller view of profit and cash flow, which the company says reflects a third consecutive year of record results.
FY2026 net sales of $1,475.0 million, compared with $1,429.7 million in FY2025.
Net income of $221.9 million, or $1.41 per diluted share, compared with $191.7 million, or $1.22 per share.
Adjusted EBITDA of $372.2 million, compared with $326.2 million; adjusted EPS of $1.57, compared with $1.31.
Free cash flow of $207.3 million, compared with $172.0 million; strategic reorganization and other charges were $27.8 million.
Consolidated Water reported third-quarter 2026 revenue of $30.9 million, down 11.9% from $35.1 million, with lower services and manufacturing revenue partly offset by higher retail and bulk revenue. Net income attributable to company stockholders fell to $2.3 million, or $0.14 per diluted share, from $5.5 million, or $0.34 per diluted share, a year earlier, so shareholders saw both lower sales and lower per-share profit.
Q3 2026 revenue $30.9 million, down 11.9% from $35.1 million; services revenue fell 31.7% to $9.8 million and manufacturing revenue fell 39.7% to $2.8 million
Q3 net income attributable to stockholders $2.3 million ($0.14 diluted EPS) vs $5.5 million ($0.34) in Q3 2025
Nine-month revenue $93.8 million, down 8.5%; cash and cash equivalents $129.2 million as of September 30, 2026
On November 6, 2026, U.S. GoldMining agreed to sell 408,163 common shares at $4.90 each to an institutional investor in a registered direct offering. Gross proceeds are expected to be about $2.0 million before offering expenses, with closing expected on or about November 9, 2026. The company plans to use the net proceeds for working capital and general corporate purposes.
Shares offered: 408,163 common shares at $4.90 per share
Expected gross proceeds: approximately $1,999,998.70 before offering expenses
Offering made under an effective Form S-3 shelf registration (File No. 333-279435) and a prospectus supplement dated November 6, 2026
Expected closing on or about November 9, 2026, subject to customary conditions
iSpecimen Inc. sold 500 shares of Series D Convertible Preferred Stock to accredited investors for aggregate gross proceeds of $400,000, closing on or about November 6, 2026. The preferred stock is convertible into common stock at a floor price of $0.1616 and can lead to dilution of up to 1,157,223 shares, or 19.99% of shares outstanding, unless stockholders approve the issuance under Nasdaq rules.
Gross proceeds of $400,000 from 500 Series D shares priced at $800 per share, with a $1,000 stated value per share
Series D accrues 8% annual cumulative dividends and converts at the greater of 85% of the prior-day closing price or a $0.1616 floor
Conversion share cap of 1,157,223 shares, or 19.99% of 5,789,013 common shares outstanding, until stockholder approval under Nasdaq Rule 5635(d)
Placement agent E.F. Hutton & Co. receives a 4.0% cash fee and 1.0% expense allowance; directors and executive officers agreed to 90-day lock-ups
At its November 9, 2026 annual meeting, Lisata Therapeutics stockholders approved the 2026 Equity Incentive Plan, the 2026 Employee Stock Purchase Plan, and a reverse stock split authorization with a ratio between 1-for-5 and 1-for-15. The vote on the Series C preferred stock conversion proposal, which would exceed 20% of outstanding common stock and result in a change of control, was not held and the meeting was adjourned. The conversion vote will resume at a reconvened meeting on November 30, 2026.
2026 Equity Incentive Plan approved with an initial reserve of 44,764,472 shares; 2,924,154 votes for and 1,552,345 against.
2026 Employee Stock Purchase Plan approved with an initial reserve of 3,730,372 shares.
Reverse stock split proposal approved with a ratio to be set by the Board between 1-for-5 and 1-for-15; 7,524,706 votes for.
Series C preferred conversion proposal not voted; reconvened meeting set for November 30, 2026 at 11:00 a.m. Eastern.
QVC Group said it will file its third-quarter fiscal 2026 results on Form 10-Q with the SEC on Monday, November 16, 2026. The company will also post an audio review of the results on its investor relations website, led by Interim CEO and Chairman Mike George and CFO Bill Wafford. The announcement gives shareholders the filing date and review format but no financial figures.
Form 10-Q for the quarter ended September 30, 2026 to be filed Monday, November 16, 2026
Audio recording reviewing results to be posted to the investor relations website
Review to be led by Interim CEO and Chairman Mike George and CFO Bill Wafford
The 8-K and press release were furnished under Regulation FD and are not deemed filed
Hallador Energy reported third-quarter 2026 results with total revenue of $130.3 million, down 11% from a year earlier but up 28% from the second quarter. The company posted a net loss of $4.5 million, compared with net income of $23.9 million a year earlier, and total debt rose to $551.9 million after a $600 million construction bridge loan tied to its Turtle Creek gas project, which it targets for a final investment decision before the end of 2026.
Q3 2026 total revenue was $130.3 million, down from $146.6 million in Q3 2025 and up from $101.5 million in Q2 2026.
Net loss was $4.5 million, versus net income of $23.9 million in Q3 2025 and a net loss of $15.2 million in Q2 2026.
Adjusted EBITDA was $17.3 million, compared with $24.9 million in Q3 2025.
Total debt rose to $551.9 million at September 30, 2026, from $45.0 million at June 30, 2026, after a $600 million senior secured construction bridge loan facility.
Douglas Elliman reported third-quarter 2026 net income of $7.4 million, or $0.08 per diluted share, compared with a net loss of $24.7 million a year earlier, while revenue fell to $252.1 million from $262.8 million. Adjusted EBITDA was a $5.3 million loss versus $1.0 million of income, and the company also approved a $10 million share repurchase program, which it says will be funded from cash on hand.
Q3 2026 revenue was $252.1 million vs. $262.8 million in Q3 2025; the company sold its property management business in October 2025.
Q3 operating income was $6.3 million vs. an operating loss of $10.7 million; Adjusted EBITDA was a $5.3 million loss vs. $1.0 million of income.
Nine-month revenue was $749.9 million vs. $787.6 million, and the net loss narrowed to $11.6 million ($0.14 per share) from $53.3 million ($0.63 per share).
The Board approved a $10 million share repurchase program; cash and a Treasury bill totaled about $123 million with no long-term debt as of September 30, 2026.
Microvast reported third-quarter 2026 revenue of $45.8 million, down 62.8% from $123.3 million a year earlier, and a net loss of $76.8 million, including $35.7 million of non-cash impairment charges. The company said its available cash is expected to be insufficient to meet obligations over the next twelve months, and its going concern doubt has not been alleviated, so shareholders face significant uncertainty about refinancing its debt.
Q3 2026 revenue was $45.8 million versus $123.3 million in Q3 2025; gross margin fell to 5.2% from 37.6%.
Q3 2026 net loss was $76.8 million, compared with a net loss of $1.5 million in Q3 2025.
Cash, cash equivalents and restricted cash were $124.4 million at September 30, 2026; $41.7 million of convertible bonds are due on or before January 31, 2027.
Net cash used in operating activities was $65.4 million for the nine months ended September 30, 2026.
Rani Therapeutics reported third-quarter 2026 results with contract revenue of $1.7 million, up from none a year earlier, mainly from its Chugai collaboration. Net loss rose to $8.8 million from $7.9 million as research and development and general and administrative expenses increased, and cash, cash equivalents and marketable securities fell to $45.3 million, which the company says will fund operations at least through the end of 2027.
Contract revenue was $1.7 million for the quarter ended September 30, 2026, versus no contract revenue a year earlier.
Net loss attributable to Rani was $7.7 million, compared with $5.4 million in the prior-year quarter; net loss per Class A share was $0.04, versus $0.12.
Cash, cash equivalents and marketable securities were $45.3 million at September 30, 2026, down from $53.4 million at June 30, 2026.
In October 2026 the RaniPill platform was accepted into the FDA's Emerging Technology Program; RT-114 expansion cohort data are expected by the end of 2026.
DoubleVerify said it expects the merger under its August 6, 2026 agreement to close in the fourth quarter of 2026, subject to remaining closing conditions. Under the merger, DoubleVerify will survive as a wholly owned subsidiary of Neptune BidCo US Inc., so shareholders will be affected by the completion timing and terms of the deal.
Merger Agreement dated August 6, 2026, with Neptune BidCo US Inc. (Parent) and Wallace Merger Sub Inc. (Merger Sub)
Company expects closing during the fourth quarter of 2026, subject to satisfaction or waiver of remaining conditions
After the merger, DoubleVerify continues as the surviving corporation and a wholly owned subsidiary of Parent
Filing is made under Regulation FD and restates terms of a previously announced transaction
Bain Capital Specialty Finance (BCSF) reported third-quarter 2026 net investment income of $27.7 million, or $0.43 per share, down from $28.6 million, or $0.44 per share, in the second quarter. Net increase in net assets from operations rose to $0.26 per share from $0.22, while net asset value per share fell to $16.49 from $16.65. The company also declared a fourth-quarter dividend of $0.42 per share and appointed Amrit Kanwal as an independent director, expanding the board to nine members.
Q3 2026 net investment income was $27.7 million, or $0.43 per share, versus $28.6 million, or $0.44 per share, in Q2 2026; total investment income was $59.9 million, versus $62.3 million.
Net increase in net assets from operations was $16.7 million, or $0.26 per share, versus $0.22 per share in Q2 2026; net asset value per share was $16.49 at September 30, 2026, versus $16.65 at June 30, 2026.
Board declared a fourth-quarter 2026 dividend of $0.42 per share, with a record date of December 15, 2026 and payment on or before December 29, 2026.
Amrit Kanwal, 61, was appointed an independent Class III director effective November 4, 2026, and joined the Audit, Nominating and Corporate Governance, and Compensation Committees.
Nine Energy Service reported third quarter 2026 revenue of $142.0 million, essentially unchanged from the second quarter's $141.8 million. Net loss widened to $5.1 million, or $(0.36) per share, from $4.9 million, or $(0.35) per share, and adjusted EBITDA fell to $8.3 million from $8.6 million. For shareholders, the company expects fourth quarter revenue to be flat and profitability to be modestly higher than the third quarter.
Q3 2026 revenue of $142.0 million versus $141.8 million in Q2 2026; cementing revenue rose 11% quarter over quarter.
Net loss of $5.1 million ($0.36 per share) in Q3 2026 versus $4.9 million ($0.35 per share) in Q2 2026.
Adjusted EBITDA of $8.3 million in Q3 2026 versus $8.6 million in Q2 2026.
Management expects Q4 2026 revenue to be flat and profitability to be modestly higher than Q3; total liquidity was $46.0 million at September 30, 2026.
InfuSystem furnished an investor presentation dated November 9, 2026, under Regulation FD. It shows higher profit for the third quarter and nine months of 2026 and gives estimates for 2026 proforma revenue growth of 6%-8% and a low-to-mid 20% margin. For shareholders, the figures show continued profit growth, though the estimates are company projections and not guaranteed results.
GAAP net income was $3.2 million for the quarter ended September 30, 2026, versus $2.3 million a year earlier.
Nine-month GAAP net income was $7.4 million in 2026, versus $4.6 million in 2025; nine-month adjusted EBITDA was $24.3 million versus $22.7 million.
Estimates as of September 30, 2026 call for 2026 proforma revenue growth of 6%-8%.
Trailing twelve-month net revenue was $144.4 million and liquidity was $64.1 million as of September 30, 2026; net leverage ratio was 0.32x.
Exodus Movement reported third quarter 2026 revenue of $32.5 million, up 7% from $30.3 million a year earlier, but swung to a net loss of $8.3 million attributable to the company from net income of $17.0 million in the prior-year quarter. General and administrative expenses rose 94% to $28.9 million, and the company said it expects to cut combined annual costs by about $30 million going into 2027 following the Monavate and Baanx acquisitions.
Q3 2026 revenue was $32.5 million, up 7% from $30.3 million in Q3 2025
Net loss attributable to Exodus was $8.3 million, versus net income of $17.0 million a year earlier
Adjusted EBITDA was a loss of $3.9 million, compared with positive $5.9 million in Q3 2025
Exodus is on track to reduce combined annual costs by about $30 million going into 2027
UWM Holdings Corporation announced the final subscription price for its rights offering of up to 200,000,000 Class A common shares: $2.00 per share. The price is the greater of $2.00 and 85% of the 10-day volume-weighted average NYSE sales price ending November 9, 2026, so the $2.00 floor applied. Subscription rights expire at 5:00 p.m. Eastern Time on November 12, 2026, unless extended.
Final subscription price is $2.00 per share, the greater of $2.00 and 85% of the 10-day volume-weighted average price ending November 9, 2026.
The rights offering covers up to 200,000,000 shares of Class A common stock.
Subscription rights expire at 5:00 p.m. Eastern Time on November 12, 2026, unless extended.
Exercised rights can be withdrawn until 5:00 p.m. Eastern Time on November 10, 2026, unless the offering is extended; the company may amend, withdraw or terminate the offering with consent of the Backstop Purchasers.
EquipmentShare reported third-quarter 2026 results for the period ended September 30, 2026, with total revenue up 55% year over year to $1,468 million and net income of $20 million, compared with $6 million a year earlier. Adjusted Core EBITDA rose 40% to $594 million, and management said it is confident in its full-year 2026 outlook and sees an opportunity to outperform it. For shareholders, both headline revenue and profit grew, though GAAP net income remains small relative to revenue and interest expense was $88 million in the quarter.
Total revenue rose 55% to $1,468 million from $945 million; Rental Segment revenue rose 49% to $1,113 million.
Net income was $20 million versus $6 million; Adjusted Net Income, which excludes $26 million of IPO Founders Awards stock compensation, was $46 million.
Adjusted Core EBITDA increased 40% to $594 million; net leverage fell to 3.4x from 3.7x a year earlier.
Current 2026 guidance ranges include total revenue of $5,808 million to $6,045 million and Adjusted Core EBITDA of $2,136 million to $2,224 million.
Summit Midstream reported third quarter 2026 net income of $15.9 million, compared with $5.0 million a year earlier, and raised its full-year 2026 Adjusted EBITDA guidance to $250 million to $260 million from $235 million to $255 million. Common stock dividends remain suspended, and the company's total net leverage ratio was approximately 3.9x as of September 30, 2026.
Q3 2026 net income $15.9 million vs. $5.0 million in Q3 2025; diluted EPS $0.58 vs. a loss of $0.13
Total revenues $183.0 million vs. $146.9 million a year earlier; Adjusted EBITDA $70.7 million vs. $65.5 million
2026 Adjusted EBITDA guidance raised to $250 million to $260 million from $235 million to $255 million
Common stock dividends remain suspended; Series A Preferred dividend payable to holders of record on December 1, 2026
Gores Holdings X said its unaudited financial statements for the three months ended September 30, 2025 should no longer be relied upon because of an error in calculating net loss per ordinary share. The restated basic and diluted net loss per share for that quarter is $(0.04), down from the previously reported $(0.65), while net income, the balance sheet and Trust Account amounts were not affected. Management also concluded that disclosure controls were not effective as of September 30, 2026 because of a material weakness in a review control.
Accretion of Class A shares was overstated by $27,471,919, with $31,069,071 reported instead of $3,597,152 for the three-month period.
Basic and diluted net loss per share for the three months ended September 30, 2025 is restated from $(0.65) to $(0.04).
Nine-month diluted Class B net loss per share is corrected from $(1.08) to $(1.10); the company says the error is not material.
The company has begun remediation, and WithumSmith+Brown has been briefed on the matter; the Q3 2026 Form 10-Q was filed November 9, 2026.
Tidewater reported third-quarter 2026 revenue of $360.4 million, up from $341.1 million a year earlier, and net income attributable to the company of $17.5 million, or $0.35 per diluted share, compared with a loss of $0.8 million a year earlier. The company also initiated 2027 revenue guidance of $1.70 to $1.75 billion and updated its 2026 revenue guidance to $1.43 to $1.44 billion, while closing a $500 million all-cash acquisition of Wilson Sons Ultratug Offshore.
Q3 2026 revenue of $360.4 million, up 5.3% from the second quarter of 2026
Q3 2026 net income of $17.5 million ($0.35 per diluted share), versus a $0.8 million loss a year earlier
Nine-month 2026 net income of $45.3 million, down from $114.8 million in the first nine months of 2025
2027 revenue guidance of $1.70 to $1.75 billion; 2026 revenue guidance updated to $1.43 to $1.44 billion
Reed's closed a private placement on November 9, 2026, issuing common stock to its majority stockholder, D&D Source of Life Holding, Ltd., for approximately $10.0 million in gross proceeds before offering expenses. The proceeds satisfied a requirement under the company's Senior Secured Loan and Security Agreement, as amended, to receive at least $10.0 million in cash equity contributions by November 20, 2026. The filing does not state the number of shares issued.
Issued common stock to majority stockholder D&D Source of Life Holding, Ltd. on November 9, 2026
Aggregate gross proceeds of approximately $10.0 million, before offering expenses
Met the loan agreement's requirement of at least $10.0 million in cash equity contributions due by November 20, 2026
Purchase Agreement was entered into October 28, 2026; its form was filed as Exhibit 10.1 to the November 3, 2026 8-K
JBS N.V. agreed to acquire Flora Produtos de Higiene e Limpeza S.A., a Brazilian personal care and household products company, from its controlling shareholder J&F, in a transaction valued at US$542 million including assumed debt. JBS also agreed to buy Canal Rural, a Brazilian agribusiness media company, for R$88.1 million, and both deals are related-party transactions to be paid mainly in JBS Class A shares, which would add to the share count and dilute existing holders.
Flora: R$2.968 billion purchase price (US$542 million enterprise value); equity consideration of US$367 million to be paid in JBS Class A shares and/or BDRs
Canal Rural: R$88.1 million purchase price, paid to J&F in Class A shares; the Ex-99.1 release gives a US$11 million transaction value
Share issuance is based on a reference price of R$66.82916 per share (US$12.20 30-day volume-weighted average), with about 31.4 million treasury shares, or 2.9% of the share count, cited in the market presentation
Both agreements were signed November 9, 2026, and the transactions are expected to close in December 2026, subject to customary closing conditions
GMR Solutions reported third quarter 2026 net revenue of $1,595.6 million, up 5.9%, and net income of $135.6 million, up 81.7%, and updated its full year 2026 guidance. Adjusted EBITDA rose 4.2% to $356.6 million in the quarter, but nine-month Adjusted EBITDA grew only 0.4%, and the filing does not state the prior guidance, so the direction of the update cannot be judged from it.
Q3 2026 net revenue $1,595.6 million, up 5.9% from $1,506.9 million; net income $135.6 million, up from $74.6 million
Q3 2026 Adjusted EBITDA $356.6 million, up 4.2%; nine-month Adjusted EBITDA $946.1 million, up 0.4%
Updated full year 2026 guidance: net revenue $5,900 million to $6,050 million; Adjusted EBITDA $1,135 million to $1,195 million
Liquidity of approximately $999.3 million at September 30, 2026, including $298.0 million of cash; $200.0 million of term loan repaid in a September 17, 2026 repricing
AGNT, Inc. entered into a Termination and Release Agreement with founder Glenn Sanford, effective retroactively to October 8, 2026, the date his employment ended in connection with the previously announced CEO transition. Sanford remains Chairman of the Board, and the agreement does not govern his board service. The release of claims is not yet effective, and the filing does not provide financial figures for the payments.
Separation Date is October 8, 2026; agreement signed November 9, 2026, and the release has not yet become effective.
Sanford keeps eligibility for eXp Realty revenue share at the highest front line qualifying agent tier, for as long as he holds Vested Status.
Company will pay or reimburse COBRA continuation coverage until the first anniversary of the Separation Date, subject to the release becoming effective.
A previously anticipated consulting agreement was not entered into; Sanford has no obligation to provide services.
Novanta reported third quarter 2026 results on November 9, 2026. GAAP revenue rose 23% to $305 million, while GAAP net income fell to $2 million from $10.7 million and GAAP diluted EPS fell to $0.05 from $0.30. The company also updated its full-year 2026 outlook, now expecting GAAP revenue of $1,135 million to $1,140 million, and said it closed its largest acquisition in company history, Riverpoint Medical.
Q3 2026 GAAP revenue was $305 million, up 23.1% from $247.8 million; Adjusted EBITDA rose 38.3% to $80.3 million.
GAAP operating income was $13.9 million versus $21.8 million a year earlier, and restructuring, acquisition, and related costs were $23.1 million.
Adjusted diluted EPS was $1.05, up 20.7% from $0.87; operating cash flow was $39.3 million versus $8.5 million.
For full-year 2026, the company now expects GAAP revenue of $1,135 million to $1,140 million and Adjusted EBITDA of $274 million to $277 million.
Elmet Group reported third-quarter 2026 results for the period ended October 2, 2026, with revenue up 55.6% to $79.6 million and net income of $8.3 million, or $0.24 per diluted share, compared with $1.6 million, or $0.08, a year earlier. Gross margin rose to 31.3% and open order backlog reached a company record $347.4 million, though nine-month net income fell to $3.5 million from $4.0 million and the release gives no new guidance.
Q3 revenue was $79.6 million versus $51.1 million a year earlier; gross profit margin was 31.3% versus 21.7%.
Adjusted EBITDA was $17.0 million, or 21.3% of revenue, versus $7.4 million, or 14.5%, in Q3 2025.
Q3 net income was $8.3 million, or $0.24 per diluted share, versus $0.08 per diluted share a year earlier.
Nine-month net income was $3.5 million, or $0.10 per diluted share, versus $4.0 million, or $0.20, for the nine months ended September 30, 2025.
Effective November 1, 2026, Matthew DiCanio became President and Chief Executive Officer, William K. Newton moved to Executive Chairman, and Tanner Newton became Executive Vice President and Chief Financial Officer. The filing also details new employment agreements and restricted stock grants to named executive officers, which set severance and change-in-control terms for shareholders to weigh.
Matthew DiCanio: President and CEO, base salary $785,000, target bonus 125% of base salary
William K. Newton: Executive Chairman, base salary $550,000, target bonus 85% of base salary
Tanner Newton: EVP and CFO, base salary $425,000, target bonus 75% of base salary
Restricted stock granted November 3, 2026 vests equally over four years; DiCanio received 164,894 shares
American Tower priced three registered senior unsecured note offerings totaling $1.5 billion on November 9, 2026. The notes are fungible with existing notes issued on September 14, 2026, and expected net proceeds are $1,474.9 million, which the company intends to use to repay borrowings under its $6.0 billion revolving credit facility and for general corporate purposes.
2031 notes: $450.0 million at a 5.300% interest rate, priced at 99.387% of face value
2033 notes: $500.0 million at a 5.560% interest rate, priced at 99.369% of face value
2036 notes: $550.0 million at a 5.750% interest rate, priced at 98.986% of face value
Expected net proceeds of $1,474.9 million, to repay revolver borrowings and for general corporate purposes
AST SpaceMobile reported third quarter 2026 revenue of $42.3 million, up from $14.7 million a year earlier, and a net loss attributable to common stockholders of $132.4 million, or $0.44 per share, compared with $122.9 million, or $0.45 per share, in the third quarter of 2025. The company said it remains on target for its revenue guidance of $150.0 million to $200.0 million and cited about $1.0 billion in non-dilutive Japanese government funding for satellite manufacturing and launch.
Q3 2026 total revenue was $42.3 million versus $14.7 million in Q3 2025; nine-month revenue was $88.6 million versus $16.6 million
Net loss attributable to common stockholders was $132.4 million, or $0.44 per share, versus $122.9 million, or $0.45 per share, a year earlier
Company remains on target for 2026 revenue guidance of $150.0 million to $200.0 million
Cash, cash equivalents and restricted cash were approximately $3.2 billion as of September 30, 2026
Bally's preliminary third-quarter 2026 consolidated revenue rose 21.7% year over year to $807.6 million, with growth led by Bally's Intralot B2C and North America Interactive. The company said it expects to file a Rule 12b-25 extension and its Form 10-Q within the extension period, and the figures remain subject to its close process. The results are preliminary and unaudited, so shareholders should watch for the final 10-Q.
Preliminary Q3 2026 revenue was $807.6 million, up from $663.7 million a year earlier
Bally's Intralot B2C revenue rose 22.8% to $257.5 million, while its Adjusted EBITDAR fell to $77.0 million from $86.4 million
The company expects to file a Rule 12b-25 extension and its 10-Q within the extension period
On October 1, 2026, Bally's closed Bronx project financing, receiving $400 million with $160 million more available for future draws
Energy Fuels Inc. said its board appointed Jeffrey Olsen as a director and as a member of the Audit Committee, effective immediately, on November 3, 2026. The filing describes his standard non-employee director compensation and a restricted stock unit grant, which is routine board refreshment that adds an independent voice to the audit oversight function.
Board appointed Jeffrey Olsen as director and Audit Committee member on November 3, 2026, effective immediately
Olsen received 2,078 restricted stock units granted November 3, 2026 at a grant price of $7.99 per underlying share
RSUs vest in three installments: 1,039 on January 27, 2027, 519 on January 27, 2028, and 520 on January 27, 2029
QXO Chairman and CEO Brad Jacobs said on a November 9, 2026 conference call that September sales were much stronger than expected and that the company pre-released third-quarter adjusted EBITDA of $557 million on revenue of $4.9 billion, an 11.4% margin. He also said his family office will lead a $1 billion cash investment in NYSE American-listed CKX Lands, under which he would own a majority stake and become its chairman and CEO while remaining QXO's chairman and CEO.
Preliminary Q3 adjusted EBITDA of $557 million on revenue of $4.9 billion, an adjusted EBITDA margin of 11.4%
Companywide pricing improved 2.2% year-over-year in Q3; daily sales rose 5.4% year-over-year across the company in October
$1 billion CKX investment: $900 million from Jacobs Private Equity and $100 million from co-investors led by Heritage Partners, with CKX stockholder approval still required
Long-term target of $4 billion adjusted EBITDA by 2030 before additional acquisitions, versus roughly $1.75 billion in current consensus estimates
NIKE appointed Dan McKenzie as Vice President, Chief Accounting Officer, Finance Operations & Transformation, and principal accounting officer, effective November 9, 2026. As of the same date, CFO David Denton stops serving as Interim Corporate Controller and principal accounting officer. McKenzie retired from NIKE in July 2026 and returns under an offer letter dated November 4, 2026.
McKenzie's pay under the offer letter: $500,000 base salary, 50% target annual bonus, and a $525,000 annual long-term incentive target.
McKenzie will receive a $600,000 target-value sign-on RSU award that vests in three equal annual installments.
David Denton, Executive Vice President and CFO, ceases as Interim Corporate Controller and principal accounting officer effective November 9, 2026.
McKenzie previously served as VP, CFO, Global Operations and Technology from August 2025 to July 2026, and spent more than 19 years at NIKE.
Forge Nano Holdings said it completed its merger with HzO, Inc. on November 4, 2026, with HzO surviving as a wholly owned subsidiary. HzO stockholders were issued Forge Nano common stock as consideration, and part of that stock is held back for twelve months to secure post-closing adjustments and indemnification. The filing adds dilution from the new shares, but it does not provide HzO financial results or the effect on Forge Nano's earnings.
Merger consideration is based on a $55.0 million base purchase price, plus or minus closing cash, working capital, indebtedness and expense adjustments, divided by $10.00 per share.
Forge Nano issued 5,772,645 shares at the Effective Time, with 1,533,795 Holdback Shares held back for twelve months.
Shares received by HzO stockholders are locked up until the earlier of six months after the Effective Time or when the stock closes at or above $12.00 for 20 of 30 trading days.
HzO's CFO Jason Savod and President and COO Rachael Lerebours signed employment agreements with Forge Nano effective after the Effective Time.
Pangaea Logistics Solutions chair Richard T. du Moulin notified the Board on November 3, 2026, that he will retire as a director effective December 31, 2026. He has served on the Board since the company's 2014 IPO, and the filing says his affiliation with the company dates back more than 25 years. The filing does not name a successor.
Retirement notified to the Board on November 3, 2026, effective December 31, 2026
Du Moulin has served as a director since Pangaea's 2014 IPO and was affiliated with the company for more than 25 years
Claus Boggild, a founder and Lead Independent Director, praised his knowledge, forethought and integrity
Mesa Laboratories reported fiscal second-quarter revenue of $62.3 million, up 2.6%, and net income of $4.3 million, up 75.3%, or $0.75 per diluted share versus $0.45 a year earlier. The company also issued its first fiscal 2027 guidance, calling for revenue of $250 million to $255 million and adjusted EBITDA of $66 million to $68 million, and authorized a share repurchase of up to $40 million.
Q2 revenue $62.3 million, up 2.6%; adjusted EBITDA $17.3 million, up 21.1%, or 27.8% of revenue
Fiscal 2027 guidance (year ending March 31, 2027): revenue $250 million to $255 million; adjusted EBITDA $66 million to $68 million
Board terminated its 2005 buyback program on November 4, 2026 and authorized up to $40 million in repurchases through December 31, 2028
Savings Plan announced October 13, 2026 expects total pre-tax restructuring charges of $2.6 million to $3.4 million, mainly in the second half of fiscal 2027
Bakkt reported third-quarter 2026 revenue of $149.2 million, down 62.9% from $402.2 million a year earlier, mainly due to lower crypto trading volume and the loss of clients. The company posted net income of $14.3 million, or $0.31 per diluted share, versus a net loss of $14.9 million in Q3 2025, and the filing notes the result includes a $26.8 million non-cash gain on the Transchem warrants. It reiterated a full-year 2026 Total Transacting Volume target of approximately $3 billion and set a first-half 2027 target of approximately $6 billion.
Q3 2026 total revenue was $149.2 million versus $402.2 million in Q3 2025; net income attributable to Bakkt was $14.3 million, or $0.31 per diluted share
Adjusted EBITDA loss narrowed to $11.8 million from $14.8 million in Q3 2025 on a consistent basis
TTV was $147.9 million for Q3 2026; the company reiterated its approximately $3 billion full-year 2026 target and set an approximately $6 billion first-half 2027 target
Cash, cash equivalents and restricted cash were $37.3 million as of September 30, 2026, versus $50.7 million as of June 30, 2026
Ranger Energy Services reported third quarter 2026 revenue of $162.8 million, up from $128.9 million a year earlier but down from $176.5 million in the second quarter, with net income of $2.5 million or $0.10 per diluted share. The company also declared a quarterly dividend of $0.06 per share, payable December 4, 2026, which signals continued cash returns to shareholders.
Q3 2026 revenue was $162.8 million, versus $176.5 million in Q2 2026 and $128.9 million in Q3 2025
Net income was $2.5 million, or $0.10 per diluted share, versus $0.29 per diluted share in Q2 2026 and $0.05 in Q3 2025
Adjusted EBITDA was $20.1 million, down from $28.6 million in Q2 2026 but up from $16.8 million in Q3 2025
Quarterly dividend of $0.06 per share payable December 4, 2026, to holders of record on November 20, 2026
Genuine Parts Company's Board declared a regular quarterly cash dividend of $1.0625 per share on November 9, 2026. The dividend is payable January 5, 2027 to shareholders of record on December 4, 2026. The filing is a routine dividend declaration and reports no earnings, guidance, or other financial results.
Regular quarterly cash dividend of $1.0625 per share declared November 9, 2026
Payable January 5, 2027 to shareholders of record on December 4, 2026
Press release furnished as Exhibit 99.1; no earnings or guidance included
UnitedHealth Group appointed Madeline Bell, former president and CEO of Children's Hospital of Philadelphia, as an independent director, effective November 3, 2026, as disclosed in a November 9, 2026 filing. The appointment is a board change with no financial figures attached, and Ms. Bell has not yet been assigned to any board committee.
Madeline Bell appointed independent director, effective November 3, 2026; no committee assignments yet
Bell retired as CHOP CEO last month, after joining CHOP as a pediatric staff nurse in 1983
Director compensation follows the company's standard non-employee director program; company will enter its standard indemnification agreement with her
Perspective Therapeutics reported a third-quarter 2026 net loss of $32.4 million, or $0.27 per share, up from $26.0 million, or $0.35 per share, a year earlier, as research and development spending rose. Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026, which the company says should fund planned clinical milestones and operations into 2028.
Q3 2026 net loss was $32.4 million ($0.27 per share), versus $26.0 million ($0.35 per share) in Q3 2025; weighted average shares rose to 120.7 million from 74.3 million.
Research and development expenses were $26.1 million, up from $20.3 million; general and administrative expenses were $8.3 million, up from $7.7 million.
Cash, cash equivalents and short-term investments were about $202 million at September 30, 2026, versus about $145 million at December 31, 2025.
On October 2026, the FDA granted Fast Track Designation to PSV359 for FAP-positive solitary fibrous tumors.
GeoVax Labs appointed Tyler O'Brien as interim Chief Executive Officer and Chairman of the Board effective November 8, 2026, and added Shahin Behroyan as a director effective November 5, 2026. The filing follows the resignation of five former directors effective October 23, 2026, and it references a dispute over the termination of a former executive, Mr. Dodd, for Cause, which the company says could lead to severance or litigation. Shareholders face a leadership change at the top of the company while a permanent CEO is sought.
Tyler O'Brien appointed interim CEO and Chairman of the Board effective November 8, 2026; will serve until a permanent principal executive officer is appointed or designated
Shahin Behroyan appointed to the Board effective November 5, 2026, to fill a vacancy from the resignation of five former directors effective October 23, 2026
Behroyan is not yet on any committee; Board determined he is independent under Nasdaq Rule 5605(a)(2)
Forward-looking statements cite a possible dispute with Mr. Dodd over termination for Cause, with potential severance of three times base salary and target bonus
Rafael Holdings furnished an November 2026 investor presentation under Regulation FD, posted on its website from November 9, 2026. The deck restates that the pivotal Phase 3 TransportNPC study for remibetadex missed its primary endpoint, with a 64% slowing of disease progression versus placebo that was not statistically significant (p=0.19), and that a New Drug Application was submitted in October 2026. The filing also cites substantial doubt about the company's ability to continue as a going concern and its need for additional capital.
Primary endpoint: 64% slowing of disease progression versus placebo, difference −0.81 (p=0.19), described as not statistically significant; a prespecified subgroup analysis reached p=0.046.
Serious treatment-emergent adverse events: 35.9% of remibetadex participants versus 16.7% on placebo over 96 weeks.
NDA submitted October 2026; Day 60 FDA filing decision expected December 27, 2026; potential FDA action around mid-2027 if priority review is granted.
Cash balance of $22.1 million as of July 31, 2026; the forward-looking statements cite going concern doubt and need for additional capital.
Vestis Corporation said its Vice President and Chief Accounting Officer, John Laveck, will resign effective December 11, 2026, to pursue an opportunity outside the company's industry. The company said the resignation is not due to any disagreement over operations, policies or practices, and a search for a replacement has begun.
John Laveck notified the company of his resignation on November 4, 2026, effective December 11, 2026.
Russell T. Tiejema, Executive Vice President and Chief Financial Officer, will act as principal accounting officer until a successor is appointed.
The filing states Mr. Tiejema will receive no additional compensation for the added role.
Briefs are written by AI from the filing text and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the AI's reading of the filing for shareholders, not a price forecast. Not investment advice.
Briefs marked “Written later” were written in November 2026 for filings that were by then more than three weeks old, so months before mid-October 2026 hold a selection: every material 8-K of the past year for the 100 largest companies we cover and the last 15 important 8-Ks of every other one. Briefs the number check holds back are not shown or counted. Also: the last 45 days, briefs by company, A–Z and the live SEC filings wire.